Eli Lilly's lead in the obesity race has increased. Its recent stock performance says otherwise.
Eli Lilly investors have received some very good news in recent months, with one notable exception regarding the stock's performance.…
investment strategy
Innovative biotech stocks have a good chance of breaking out in 2025
The trends may be turning in favor of biotech stocks in 2025 after several years of poor performance, but it…
Danaher had a disappointing 2024. Your path to success next year passes through Wall Street
Life sciences company Danaher certainly hasn't been an easy stock to buy this year. A wave of new companies going…
Eli Lilly seeks to extend its winning streak in the general market to 6 years
Eli Lilly has outperformed the S&P 500 for five straight years as Wall Street realized its huge opportunity in obesity…
CFPB sues JPMorgan Chase, Bank of America and Wells Fargo over Zelle fraud
Rohit Chopra, Director of the CFPB, testifies during the Senate Committee on Banking, Housing and Urban Affairs hearing titled “Semi-Annual…
We're adding to our position in a stock that just got some big support from Wall Street.
Shortly after the bell rings, we will buy 300 shares of Bristol Myers Squibb at approximately $56.50. Following the deal,…
We want to increase our ownership of a portfolio stock that just increased its dividend.
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Our newest portfolio stocks pulled back from their recent 52-week high, so we're buying more
We are buying 300 shares of Bristol-Myers Squibb at approximately $58 each. Following Wednesday's trade, Jim Cramer's Charitable Trust will…
United Healthcare CEO Shooting: Executives Worry About Safety
Closed-circuit screenshots of a person of interest in the murder of UnitedHealthcare CEO. Source: NYPD UnitedHealthcare CEO Brian Thompson was…
Eli Lilly's obesity drug beats rival in head-to-head trial, where Cramer thinks stock will be next
The new trial data has cemented Club's lead position behind Eli Lilly in the highly competitive anti-obesity drug race. Eli…